Daniel Alpern

Chief Scientific Officer, Alithea Genomics

Daniel Alpern is listed as Chief Scientific Officer, Alithea Genomics. Daniel is scheduled to speak at SLAS 2027 International Conference & Exhibition on 3 February 2027.

Compiled from published conference agendas; not yet confirmed by Daniel. Is this you? Claim this profile.

About

Daniel Alpern, PhD, is co-founder and Chief Scientific Officer at Alithea Genomics, a leading company in high-throughput RNA sequencing technologies for drug discovery and biomarker research. He earned his PhD in molecular biology from Moscow State University and subsequently conducted postdoctoral research in France and Switzerland, focusing on transcriptional regulation and genetic variation. Before co-founding Alithea in 2020, his research at the École Polytechnique Fédérale de Lausanne (EPFL) led to the development of BRB-seq, a technology that underpins Alithea’s transcriptomics platforms.

Upcoming

SLAS 2027 International Conference & Exhibition 30 January 2027 – 3 February 2027

Beyond Morphology: 1536-Well Transcriptomics for MoA Discovery and Chemical–Genetic Mechanism Mapping Speaker · 3 February 2027